Intravitreal bevacizumab for treatment of refractory central serous choroidoretinopathy |
| |
Authors: | Entezari Morteza Ramezani Alireza Yaseri Mehdi |
| |
Affiliation: | Ophthalmic Research Center, Department of Ophthalmology, Imam Hossein Medical Center, Shahid Beheshti University, Tehran, Iran. entmort@hotmail.com |
| |
Abstract: | In a clinical case series, 5 patients with not-resolved central serous choroidoretinopathy (CSC) lasting more than 1 year received one intravitreal bevacizumab injection (IVB, 1.25 mg) injection. All patients underwent a through ophthalmic examination 1 day, 1 week, and 1, 2, and 6 months after the injection. Best corrected visual acuity (BCVA) and central macular thickness were compared before and after treatment by optical coherence tomography. Mean BCVA was improved significantly (p = 0.020) from 0.60 ± 0.25 to 0.50 ± 0.18 and 0.29 ± 0.19 logarithm of minimum angle of resolution at 6 and 18 weeks, respectively. Central macular thickness was also decreased significantly (p = 0.010) from 370 ± 65 to 208 ± 23 μm at 4 months. No recurrence was occurred during follow-up. IVB injection may have beneficial effect in the treatment of refractory CSC. |
| |
Keywords: | Bevacizumab Central serous choroidoretinopathy Optical coherence tomography |
本文献已被 PubMed 等数据库收录! |
|